IV Route Could Complicate Picture
Tysabri's Physician Uptake Remains Question Mark
By Randall Osborne
Monday, November 29, 2004
Earlier this month when Biogen Idec Inc. at last unveiled one-year data from its Phase III trial known as AFFIRM, hopes of investors - not to mention multiple sclerosis patients - ran high for the would-be blockbuster Antegren (natalizumab).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.